Why Scynexis Shares Are Falling During Thursday’s After-Hours Session
SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the offering was not disclosed.
SCYNEXIS To Present Interim Data From Its Ongoing FURI, CARES Studies At European Congress Of Clinical Microbiology, Infectious Diseases Apr. 25
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data from its
HC Wainwright & Co. Maintains Buy on SCYNEXIS, Lowers Price Target to $14
HC Wainwright & Co. analyst Oren Livnat maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and lowers the price target from $20 to $14.
Looking Into SCYNEXIS’s Return On Capital Employed
SCYNEXIS (NASDAQ:SCYX) brought in sales totaling $597.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 4733.55%, resulting in a loss of $29.24 million.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) jumped 88.1% to $0.38 after declining 9% on Monday.
SCYNEXIS Q4 EPS $(1.05) Misses $(0.77) Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.77) by 36.36 percent. This is a 72.22 percent increase over losses of $(3.78) per share from the
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell
• 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.